Crescent Capital BDC has 191 portfolio companies with a focus on middle-market firms. CCAP faces increasing credit issues and new non-accruals impacting its profitability. Recent changes in special dividends could drive investor concern for CCAP. The stock trades at a 23% discount to NAV amid challenging market conditions. CCAP maintains an 11% yield on its base dividend, attracting potential bargain hunters.
Crescent Capital BDC has 89.2% first-lien debt, indicating high portfolio quality. CCAP is sensitive to interest rate cuts, affecting floating-rate debt investments. Strong net investment income supports well-covered dividends for CCAP. Trading at a slight premium to NAV offers an attractive entry point. Crescent Capital’s defensive portfolio and activity warrant a strong buy rating.
Crescent Capital BDC has a strong defensive portfolio with 89.2% first-lien debt. Interest rate sensitivity could affect CCAP, but lower expenses may offset impacts. CCAP's dividends are well-covered, indicating strong overall financial health. Currently trading at a slight premium, CCAP is seen as an attractive entry point.
CCAP's portfolio valued at $1.6 billion shows strong management performance. Current NII of $0.59 per share comfortably covers the $0.42 dividend. Only 0.8% of the portfolio is at risk of non-accrual status. CCAP's discount to NAV is lower than the historical average of 19%. The BDC's strong NII coverage supports dividend stability even amidst rate changes.
